"Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 180,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group (NYSE:UNH)."

During the past decade, Clinical Research Advantage conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 9 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinical Research Advantage" #1 sponsor was "Abbott Nutrition" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Arbor Pharmaceuticals, Inc." with 1 trials sponsored, "AstraZeneca" with 1 trials sponsored and "Bristol-Myers Squibb" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinical Research Advantage" #1 collaborator was "CoLucid Pharmaceuticals" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Triangle Biostatistics" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Clinical Research Advantage" are "Acute Migraine" (1 trials), "Acute Otitis Externa" (1 trials), "Gastrointestinal Tolerance" (1 trials), "Growth and Tolerance" (1 trials) and "Healthy" (1 trials). Many other conditions were trialed in "Clinical Research Advantage" in a lesser frequency.

Most popular intervention types in "Clinical Research Advantage" are "Drug" (8 trials), "Other" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Metformin XR" (2 trials), "AR08" (1 trials), "Androxal" (1 trials) and "Bococizumab (PF-04950615; RN316)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Clinical Research Advantage" are 10 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Clinical Research Advantage". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Clinical Research Advantage, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Clinical Research Advantage, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".